Executive Team

Richard A. Basile
– Co-Founder and CEO

Mr. Basile is a biopharmaceutical executive with 35 years of international biopharmaceutical industry experience with early-stage and Fortune 100 Pharma/Biotech companies, including licensing, mergers and acquisitions, product development, sales, marketing and launch in anti-infective, cardiovascular, immunological, dermatologic, CNS and metabolic disease segments, including biotechnology and protein therapeutic products such as Factor VIII for treatment of a rare clotting disorder, Hemophilia. Mr. Basile served as the global Vice President of corporate strategy, finance, and business development of a $1.2 billion international biologics business unit at Bayer AG (Bayer Biologicals). Mr. Basile also served in several senior marketing, sales and strategic marketing capacities’ at Bayer Pharmaceuticals, and was President and General Manager of a Bayer subsidiary, Rhein Chemie Corporation. More recently, Mr. Basile was the founding CEO of Entegrion (formerly Hemocellular Therapeutics), an early stage biotech company founded on UNC-CH invention in homeostasis, Executive VP at MylanBertek, and was the global commercial head of Diosynth Biotechnology, part of Organon Biosciences where he also served on the executive management team of Organon (now Merck & Co) responsible for biotechnology business development, with focus on oncology and immunology. As a founder of BioPontis Alliance, Mr. Basile has frequently advocated for a new paradigm in advancing academic research into cures, and has presented to the National Academy’s (Government University Industry Research Roundtable) among other government, academic and industry conferences.

(919) 345-5386

Gilbert W. Carnathan,

Dr. Gilbert (Chip) Carnathan is a career pharmaceutical executive with extensive experience in drug discovery and drug development and joined BioPontis Alliance Rare Disease Foundation as Chief Scientific Officer on August 1, 2018. As a consultant he has collaborated with both start-up biotechnology and established pharmaceutical companies to design innovative and expeditious US and global drug development strategies. In addition, he represents these companies in their interactions with FDA. Prior to BioPontis, his most recent projects have been as an independent consultant; however, Chip has served in consulting roles as the President of Origin USA LLC, Senior Director of US Regulatory Affairs at SRA International and as Senior Director of Regulatory Affairs at Impact Pharmaceuticals. At these CROs, he was responsible for the development of US and International regulatory strategies, the management of sponsored regulatory programs, and the design of preclinical development programs. In addition to his extensive experience as a consultant, Chip served as the Vice President responsible for preclinical research and development efforts at three biotechnology companies: Cortech, Napro Biotherapeutics, and Argos Therapeutics. During a career spanning more than 35 years, Chip has played a key role in advancing more than 25 drugs, biologics, and vaccines into clinical development in the US, Europe, and Africa. Chip earned his PhD in Reproductive Pharmocology at the University of Massachusetts, Amherst.

(919) 452-7676